



Gilead Announces an Independent Medical Education Grant Request for Proposals (RFP)

Clinical Laboratory Preparations for Patients Receiving Anti-CD47 Monoclonal Antibody Agents

Competitive Grant Program

Background:	<p>Gilead Sciences is committed to supporting independent educational initiatives addressing clinical practice gaps to improve the care of patients receiving monoclonal antibody agents.</p> <p>Independent Medical Education Programs (IMEP) must be free of commercial bias. Accredited IMEPs must comply with current Accreditation Council for Continuing Medical Education (ACCME) or other relevant accrediting organization rules and applicable regulations, rules, and guidelines. Both accredited and non-accredited IMEPs must be independent of Gilead’s influence based upon the factors described in the FDA’s Guidance for Industry on Industry-Supported Scientific and Educational Activities and other applicable regulations, rules, and guidelines. Funding or support for IMEPs may not be provided except as specified in this Policy.</p> <p>Gilead may publish RFPs online through the Alliance for Continuing Education in the Health Professions (ACEhp). This RFP may also be distributed to all educational providers who have previously completed successful independent education activities supported by Gilead within a year from the time of this RFP publication.</p>
Clinical Area:	<p>Oncology</p> <p>This RFP is for independent medical education grants focused on clinical laboratories and blood bank screening, testing, and transfusing patients receiving anti-CD47 monoclonal antibody agents.</p>
Health Care Gaps^{1,2}:	<p>The purpose of this independent medical education request for healthcare professionals is to address health care gaps and to ensure that existing guidelines and best evidence is being incorporated into clinical practice. Some examples of identified needs could include the following:</p> <ul style="list-style-type: none"> • Anti-CD47 agents may have clinically relevant effects on red blood cells, transfusion requirements, and laboratory compatibility testing.

	<ul style="list-style-type: none"> • Clinicians and laboratories testing samples from patients on anti-CD47 agents should be aware of potential problems with blood compatibility testing. • Clear protocols and laboratory procedures need to be developed to facilitate timely, safe, and effective transfusion support for these patients, including evidence-based mitigation strategies as published in the literature, such as baseline testing prior to treatment. • Patients receiving anti-CD47 agents may be transfused multiple times and transfusions remain an essential component of supportive care. • Patients receiving these therapies are often regionally diverse and the nearest hospital is often not the site of initial treatment. • Patients receiving these therapies will present to both large and small, urban, and rural institutions and may require transfusions. <p><i>References:</i></p> <p><i>Tan M et al. Intern Med J. 2022 Sep 16. doi: 10.1111/imj.15934.</i></p> <p><i>Brierley CK et al. Transfusion. 2019 Jul;59(7):2248-2254. doi: 10.1111/trf.15397.</i></p>
Geographic Scope:	United States
Applicant Criteria:	<ul style="list-style-type: none"> • Applications are welcome from healthcare organizations, academic institutions both large and small; professional associations/societies; medical education companies; and other organizations interested in improving engagement in care for patients receiving anti-CD47 agents. • This RFP is for independent medical education grants only. This RFP is not intended to support clinical research projects or programs evaluating the efficacy of therapeutic agent(s) and/or diagnostic agent(s).
Target Audience:	Clinical laboratory and blood bank personnel who care for, and/or support patients receiving anti-CD47 agents.

Format:	<p>Any activity format that educates the target audience of blood bank personnel is acceptable, including, but not limited to, a live independent satellite symposia (ISS) or online education. Applications utilizing innovative methods or technologies that include the patient perspective, as well as those building on successful evidence-based strategies are encouraged.</p> <p>Applications should include the following:</p> <ul style="list-style-type: none"> • A timeline for program completion of \leq 13 months after the ISS. • Additional resources are not required, but if included in the activity design, please provide a description.
Grant Funding:	<p>Individual applications requesting up to \$350,000 will be considered.</p>
Key Dates:	<ul style="list-style-type: none"> • RFP release date: February 10, 2023 • Phase 1: Program Overview (see below) due Feb 24, 2023 • Phase 1 Decisions communicated no later than March 10, 2023 • Phase 2: Complete proposal applications will be accepted until 23:59 Eastern Standard Time, March 31, 2023 (Note: Submissions will be reviewed as they are received) • Grant award notification: April 30, 2023
Instructions for Submission:	<ul style="list-style-type: none"> • Phase 1: Program Overview <ul style="list-style-type: none"> ○ 1–2-page summary ○ Include: brief description of clinical practice gaps and educational needs, educational objectives, program design and components, outcomes plan, and estimate of cost ○ Send to Tony Martin (Tony.Martin7@gilead.com) with “RFP anti-CD47 education – [title of the program]” in the subject line ○ You will be notified if your program concept will move forward to Phase 2 • Phase 2: Complete application submitted for formal review <ul style="list-style-type: none"> ○ Please go to https://www.gilead.com/purpose/giving/grant-funding and scroll down to the bottom of the page to sign in. ○ Note: If your organization has not previously applied for a grant at Gilead, you will need to create an account. ○ If you are a new user and a for-profit medical education provider, you will need to create an account and complete the Educational Provider Form. • In the application, please ensure the following: <ul style="list-style-type: none"> ○ For the ‘Grant Type’, select IMED

	<ul style="list-style-type: none"> ○ For the ‘Therapeutic Area’ select Oncology (Targeted and Immunotherapies) ○ For the ‘Primary Therapeutic Area’, select MDS ○ For ‘Gilead Contact’, list Tony Martin (RFP – anti-CD47 education) <p>Please complete all required sections of the online application, including a completed version of the Gilead 60-30-10 LOA Template. Upload your project proposal under the ‘Supporting Documents’ field - additional supporting documents may be included in this section.</p> <p>Project proposal should include the following:</p> <ul style="list-style-type: none"> ● Needs Assessment: Include a comprehensive needs assessment from your organization. ● Target Audience: Describe the primary target audience for this program as well as methods for reaching the intended target audience. ● Program Design: Describe the planned program and educational approach. If this program is utilizing digital and/or innovative technologies or if the program is building upon existing and/or proven strategies, please include a description. ● Learning Objectives: Provide clearly defined and measurable learning objectives for this program. ● Program Evaluation and Outcomes: Provide a description of the methods that will be utilized to determine if the program/activity has served to address the gaps of the target audience. Outcomes up to level 5 preferred. ● Enduring Component: Provide an opportunity for learners to access the educational content on-demand following the live ISS.
Questions:	If you have questions regarding this RFP, please direct them to Tony Martin (Tony.Martin7@gilead.com) with the subject line “RFP – anti-CD47 education”
Grant Agreements:	<ul style="list-style-type: none"> ● All approved grants will be required to enter into a Letter of Agreement (LOA) with Gilead. The terms of the LOA can be viewed in the Gilead Grants Portal under the ‘LOA Documentation’ field. ● Gilead LOA terms will need to be accepted in their entirety. Please ensure that your organization has reviewed these terms and is willing to abide by these terms before submitting your grant application.

Evaluation and Review Process:	<ul style="list-style-type: none">• Grant requests will be comprehensively reviewed and evaluated on the same criteria. Requests that best meet the healthcare gaps and are aligned with Gilead’s Medical Education Priorities will be recommended for approval as budget permits. Applicants may be asked for additional information and/or clarification during the evaluation and review process.
Grant Decision:	<ul style="list-style-type: none">• Grant decisions will be communicated to the grant applicant via email notification.